NCT03804996 2024-04-08
Study of TG-1801 in Subjects With B-Cell Lymphoma
TG Therapeutics, Inc.
Phase 1 Completed
Clinical Trials
8 trialsNCT04508647 2024-03-21
Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma
University of Colorado, Denver
Phase 2 Completed
NCT01647971 2022-11-21
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TG Therapeutics, Inc.
Phase 1/2 Completed
NCT02013128 2022-10-24
Ublituximab + Ibrutinib in Select B-cell Malignancies
TG Therapeutics, Inc.
Phase 1/2 Completed
NCT02535286 2022-10-20
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
TG Therapeutics, Inc.
Phase 1 Completed
NCT02301156 2022-05-20
GENUINE
TG Therapeutics, Inc.
Phase 3 Completed
NCT02006485 2019-11-05
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
TG Therapeutics, Inc.
Phase 1 Completed
NCT01098188 2012-04-30
LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia
Laboratoire français de Fractionnement et de Biotechnologies
Phase 1 Completed